相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease
Grazia Pennisi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Association Between PNPLA3 rs738409 C > G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease
Stefania Grimaudo et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease
Stefano Romeo et al.
CELL METABOLISM (2020)
Update on NAFLD genetics: From new variants to the clinic
Eric Trepo et al.
JOURNAL OF HEPATOLOGY (2020)
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis
Serena Pelusi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2019)
Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension
Georg Semmler et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
Zobair M. Younossi et al.
LANCET (2019)
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver
P. Dongiovanni et al.
JOURNAL OF INTERNAL MEDICINE (2018)
Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
B. Hameed et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2018)
FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver
Romeo Papazyan et al.
JOURNAL OF LIPID RESEARCH (2018)
Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
Toshihiro Goto et al.
SCIENTIFIC REPORTS (2018)
Farnesoid-X Receptor single nucleotide polymorphism rs35724 is potentially associated with patients' outcome in decompensated liver cirrhosis
N. F. Mueller et al.
JOURNAL OF HEPATOLOGY (2017)
Farnesoid-X Receptor (FXR) as a Promising Pharmaceutical Target in Atherosclerosis
Demetrios Moris et al.
CURRENT MEDICINAL CHEMISTRY (2017)
Nuclear receptors and nonalcoholic fatty liver diseases
Matthew C. Cave et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2016)
MERTK rs4374383 polymorphism affects the severity of fibrosis in non-alcoholic fatty liver disease
Salvatore Petta et al.
JOURNAL OF HEPATOLOGY (2016)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri et al.
LANCET (2015)
Obeticholic Acid, a Farnesoid X Receptor Agonist, Improves Portal Hypertension by Two Distinct Pathways in Cirrhotic Rats
Len Verbeke et al.
HEPATOLOGY (2014)
Exome-wide association study identifies a TM6SF2 variant that confers susceptibility to nonalcoholic fatty liver disease
Julia Kozlitina et al.
NATURE GENETICS (2014)
Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
Sunder Mudaliar et al.
GASTROENTEROLOGY (2013)
Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes
Cedric Langhi et al.
FEBS LETTERS (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
The farnesoid X receptor modulates adiposity and peripheral insulin sensitivity in mice
B Cariou et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Bile acids induce the expression of the human peroxisome proliferator-activated receptor α gene via activation of the farnesoid X receptor
IP Torra et al.
MOLECULAR ENDOCRINOLOGY (2003)
The farnesoid X-receptor is an essential regulator of cholesterol homeostasis
G Lambert et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
